Subscribe to Newsletter
Outside the Lab Oncology, Clinical care, Analytical science, Screening and monitoring

A New Gold Standard Test for PDAC?

Pancreatic ductal adenocarcinoma (PDAC) is challenging to treat – able to survive with limited blood supply and low oxygen, and with the ability to protect itself from the immune system, the disease causes few symptoms in its early stages. As a result, PDAC is often diagnosed when the disease is more advanced – and when the prognosis for patients tends to be bleak.

Earlier diagnosis is likely to translate to improved survival, so a team of researchers, including Cesar Castro, Assistant Professor of Medicine at Harvard Medical School, have developed a new diagnostic assay that performs better than the current blood test and has the potential to diagnose PDAC earlier. “No current blood-based laboratory test exists to reliably identify early PDAC without high rates of false positives, causing undue alarm for both patients and providers,” said Castro. “With reliable early detection methods, we would expect significant rather than incremental improvements for patient survival,” he added.

The test uses nanotechnology to detect tumor-derived extracellular vesicles (tEVs) in plasma. These vesicles, which are structurally stable, relatively abundant, and have a biological makeup very similar to the main tumor, should be able to act as “serial peripheral windows” into PDAC tumors, without the need for tissue biopsy, according to Castro.

The tEVs are detecting using a plasmonic sensing system, in which the light emitted through gold nanopores is measured – the tEVs are bound via monoclonal antibodies immobilized on the surface of the pores, and this causes a spectral shift in the light that passes through the pores.

After initially studying around 50 proteins, the team found that individual tEV markers didn’t appear to be accurate enough to be clinically useful in isolation. However, a panel of five tEVs produced an accuracy of 84 percent, a sensitivity of 86 percent and a specificity of 81 percent when differentiating PDAC from other pancreatic diseases (1). Analysis takes 10 minutes and costs US$60 per patient – $42 for the chip, and $18 for the cost of the antibodies.

“Rather than seeking one universal, yet elusive PDAC marker that likely does not exist given human biological complexity, our work identified a multi-component PDAC signature with excellent diagnostic performance,” said Castro. Next, the team plans to demonstrate the real-world performance of the test, and look into its potential use for screening patients at high risk of developing PDAC.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. KS Yang et al., “Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy”, Sci Transl Med, 9, eaal3226 (2017). PMID: 28539469.
About the Author
Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as an Associate Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

Related Application Notes
Tumor Genomic Profiling with SureSelect Cancer Tumor-Specific Assays

| Contributed by Agilent

Comprehensive Genomic Profiling with SureSelect Cancer CGP Assay

| Contributed by Agilent

Preventing Bias in scRNAseq Performed on Solid Tumors

| Contributed by Revvity

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register